Formycon AG (ETR: FYB)
Germany
· Delayed Price · Currency is EUR
51.30
+0.30 (0.59%)
Dec 20, 2024, 5:36 PM CET
Formycon AG Revenue
Formycon AG had revenue of 26.89M EUR in the half year ending June 30, 2024, with 52.42% growth. This brings the company's revenue in the last twelve months to 60.80M, down -11.42% year-over-year. In the year 2023, Formycon AG had annual revenue of 77.70M with 82.83% growth.
Revenue (ttm)
60.80M
Revenue Growth
-11.42%
P/S Ratio
14.04
Revenue / Employee
254.39K
Employees
238
Market Cap
905.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
Dec 31, 2019 | 33.16M | -9.84M | -22.88% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionFormycon AG News
- 12 days ago - EQS-News: MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region - Wallstreet:Online
- 22 days ago - Formycon AG (XTER:FYB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges - GuruFocus
- 22 days ago - Q3 2024 Formycon AG Earnings Call Transcript - GuruFocus
- 23 days ago - Formycon's 2024 Growth Soars with Strong Nine-Month Results - Wallstreet:Online
- 23 days ago - EQS-News: Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea under the tradenames AHZANTIVE and Baiama - Wallstreet:Online
- 5 weeks ago - EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE/ Baiama receives positive CHMP Opinion from EMA - Wallstreet:Online